Stocks and Investing
Stocks and Investing
Mon, December 16, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, December 13, 2019
Esther Rajavelu Initiated (ARWR) at Hold on, Dec 13th, 2019
Esther Rajavelu of Oppenheimer, Initiated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold on, Dec 13th, 2019.
Esther has made no other calls on ARWR in the last 4 months.
There are 4 other peers that have a rating on ARWR. Out of the 4 peers that are also analyzing ARWR, 1 agrees with Esther's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Elemer Piros of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $50 on, Tuesday, November 19th, 2019
These are the ratings of the 3 analyists that currently disagree with Esther
- Joel Beatty of "Baird" Upgraded from Hold to Buy and Increased Target to $70 on, Monday, November 25th, 2019
- Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $59 on, Wednesday, November 13th, 2019
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $45 on, Tuesday, October 22nd, 2019